AU2002344178A1 - Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus - Google Patents

Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus

Info

Publication number
AU2002344178A1
AU2002344178A1 AU2002344178A AU2002344178A AU2002344178A1 AU 2002344178 A1 AU2002344178 A1 AU 2002344178A1 AU 2002344178 A AU2002344178 A AU 2002344178A AU 2002344178 A AU2002344178 A AU 2002344178A AU 2002344178 A1 AU2002344178 A1 AU 2002344178A1
Authority
AU
Australia
Prior art keywords
thiol
microm
effector
diabetes mellitus
glutathione metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002344178A
Other languages
English (en)
Inventor
Siegfried Ansorge
Gerhard Fries
Dieter Koegst
Michael Tager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMTM GmbH
Z&Z Service GmbH
Original Assignee
Esparma GmbH
IMTM GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esparma GmbH, IMTM GmbH filed Critical Esparma GmbH
Publication of AU2002344178A1 publication Critical patent/AU2002344178A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002344178A 2001-05-28 2002-05-27 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus Abandoned AU2002344178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10125882.8 2001-05-28
DE10125882A DE10125882B4 (de) 2001-05-28 2001-05-28 Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
PCT/EP2002/005811 WO2002096398A2 (de) 2001-05-28 2002-05-27 Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
AU2002344178A1 true AU2002344178A1 (en) 2002-12-09

Family

ID=7686361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002344178A Abandoned AU2002344178A1 (en) 2001-05-28 2002-05-27 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus

Country Status (9)

Country Link
US (1) US7429614B2 (enExample)
EP (2) EP1529529B1 (enExample)
JP (1) JP4746258B2 (enExample)
AT (2) ATE429911T1 (enExample)
AU (1) AU2002344178A1 (enExample)
DE (3) DE10125882B4 (enExample)
ES (2) ES2247377T3 (enExample)
PT (1) PT1529529E (enExample)
WO (1) WO2002096398A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303229B4 (de) 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol und Inhibitoren des Angiotensin Converting-Enzyms (ACE) umfassende Arzneimittel Arzneimittel-Zubereitung und ihre Verwendung zur Behandlung von neurodegenerativen Erkrankungen
DE10360954B3 (de) * 2003-12-23 2005-08-18 Esparma Gmbh Verwendung von Silibinin, dessen Salzen und/oder dessen Prodrugs zusammen mit α-Liponsäure zur Behandlung chronisch obstruktiver Lungenerkrankungen
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US20100099751A1 (en) * 2008-10-21 2010-04-22 Al-Mulla Fahd Method of treating diabetes-related vascular complications
KR20110103987A (ko) * 2008-12-01 2011-09-21 인베이스크 테라퓨틱, 인크. 레닌-안지오텐신 알도스테론계 억제제 및 리포산 화합물을 포함하는 조성물, 및 레닌-안지오텐신 알도스테론계 관련 질환의 치료를 위한 이의 용도
CN113244265B (zh) * 2021-03-23 2023-07-14 武汉广行科学研究有限公司 配体修饰的硫化锌纳米粒子、制备方法及其在治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03169813A (ja) * 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
DE4420102A1 (de) * 1994-06-09 1995-12-14 Asta Medica Ag Arzneimittelkombinationen aus alpha-Liponsäure und herz-kreislaufaktiven Substanzen
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
US6133304A (en) * 1997-12-23 2000-10-17 Warner-Lambert Company ACE inhibitor-MMP inhibitor combinations
DE19806354B4 (de) * 1998-02-10 2004-09-16 Bdd Group Holding Ag Verwendung von α-Liponsäure oder deren physiologisch verträgliche Salze zur Behandlung von LDL-Hypercholesterinämie
JP2000309543A (ja) * 1999-04-28 2000-11-07 Ajinomoto Co Inc 抗糖尿病剤
DE10125883A1 (de) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie

Also Published As

Publication number Publication date
ES2322257T3 (es) 2009-06-18
ES2247377T3 (es) 2006-03-01
DE10125882A1 (de) 2002-12-12
JP2004531567A (ja) 2004-10-14
WO2002096398A3 (de) 2003-02-27
EP1392288A2 (de) 2004-03-03
DE50204093D1 (de) 2005-10-06
ATE429911T1 (de) 2009-05-15
EP1529529B1 (de) 2009-04-29
ATE303145T1 (de) 2005-09-15
DE10125882B4 (de) 2007-03-29
US20040138311A1 (en) 2004-07-15
PT1529529E (pt) 2009-05-11
JP4746258B2 (ja) 2011-08-10
DE50213511D1 (de) 2009-06-10
EP1529529A1 (de) 2005-05-11
EP1392288B1 (de) 2005-08-31
US7429614B2 (en) 2008-09-30
WO2002096398A2 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
US6011067A (en) Antioxidant composition for the treatment of psoriasis and related diseases
WO2003061768A3 (fr) Utilisation d'un compose inactivant la proteine kinase a dans une composition contenant un milieu cosmetiquement acceptable, pour eclaircir la peau
Raat et al. Effects of nitrite on modulating ROS generation following ischemia and reperfusion
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2001021159A3 (en) Pharmaceutical composition of nateglinide and another antidiabetcagent
WO2003033524A3 (en) Peptidyl ketones as inhibitors of dpiv
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
HU9601154D0 (en) Matrix metalloprotease inhibitors
Arivazhagan et al. Effect of DL-α-lipoic acid on neural antioxidants in aged rats
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
AU2002344178A1 (en) Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus
EP1197210A4 (en) MEANS TO PREVENT THE CHRONIC BREATHING REACTION AS A RESULT OF AN ORGANTRANSPLANTATION
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
EP1043322A4 (en) DERIVATIVES OF VITAMIN E
WO2004100884A3 (en) Oral care methods and products
WO2005092304A3 (en) Antifungal agents
BRPI0412424A (pt) composto, composição farmacêutica, método para tratar doenças dermatológicas ou cancerosas em um mamìfero, composição, e, método para tratar doenças relacionadas com a pele ou cancerosas
Moncada et al. Role of glutathione in the susceptibility of Trypanosoma cruzi to drugs
WO2001074807A1 (en) Indolylpyrrole derivatives and cell death inhibitors
Fernández-Tomé et al. Neuroprotective effects of DETA-NONOate, a nitric oxide donor, on hydrogen peroxide-induced neurotoxicity in cortical neurones
WO2003092655A3 (de) Verwendung von wirkstoffmischungen mit azelainsaure und glycyrrhetinsaure als anti-aknemittel
Lal et al. Lipoic acid and acetyl-carnitine reverse iron-induced oxidative stress in human fibroblasts
EP1391452A4 (en) 4-HYDROXPIPERIDIN DERIVATIVE ANALGETIC EFFECT
RU2285525C2 (ru) Лекарственное средство, содержащее эффектор метаболизма глутатиона вместе с альфа-липоевой кислотой, для терапии при пересадке почек
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase